Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.72 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.51 |
| ▸ | KDM5A | P29375 | 6/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.51 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.50 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505327 | 1.00 | PIK3CA (0.72) | PIK3CAKDM4CKDM5AKDM5BPROKR1 | |
| SCHEMBL31143236 | 0.98 | PIK3CA (0.74) | PIK3CAKDM4CKDM5AKDM5BPROKR1 | |
| SCHEMBL1516867 | 0.98 | PIK3CA (0.74) | PIK3CAKDM4CKDM5AKDM5BPROKR1 | |
| Hydrochloric Acid SCHEMBL1252523 | 0.97 | PIK3CA (0.72) | PIK3CAKDM4CKDM5AKDM5BPROKR1 | |
| SCHEMBL27991055 | 0.86 | PIK3CA (0.58) | PIK3CAPROKR1PRKD3PRKD1PRKD2 | |
| SCHEMBL12640115 | 0.85 | PIK3CA (0.54) | PIK3CAPROKR1PRKD3PRKD1PRKD2 | |
| SCHEMBL30290310 | 0.85 | PRKD3 (0.62) | PIK3CAKDM5BPROKR1GAAALDH1A1 | |
| SCHEMBL20951723 | 0.85 | PIK3CA (0.62) | PIK3CAKDM4CKDM5AKDM5BPROKR1 | |
| SCHEMBL12552657 | 0.84 | PIK3CA (0.60) | PIK3CAKDM4CKDM5AKDM5BPROKR1 | |
| SCHEMBL1255470 | 0.84 | PIK3CA (1.00) | PIK3CAKDM4CKDM5AKDM5BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-116457352-A | Aryloxazolo spiro derivatives for the treatment and prophylaxis of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022112140-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-20180148440-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-05-31 | — | — | US | disclosed |
| EP-3002283-B1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2804868-B1 | PYRAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20170037042-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-09 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
| EP-1812072-A2 | BENZOTHIAZOLE FORMULATIONS AND USE THEREOF | Ares Trading S.A. (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007075896-A2 | HETEROCYCLIC CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006053882-A2 | BENZOTHIAZOLE FORMULATIONS AND USE THEREOF | ARES TRADING S.A. (CH) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006010082-A1 | 1,4-DISUBSTITUTED NAPHTALENES AS INHIBITORS OF P38 MAP KINASE | ARQULE, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148440-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, P2RX1 | PIK3CA 1842/4885KDM4C 3408/4885KDM5A 4132/4885 |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | MGLL, MBOAT4, MBOAT1 | PIK3CA 2891/4885KDM4C 3044/4885KDM5A 2718/4885 |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK8, MAPK4 | PIK3CA 2806/4885KDM4C 4381/4885KDM5A 4241/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | PIK3CA 941/4885KDM4C 4495/4885KDM5A 4596/4885 |
| US-20170037042-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, P2RX1 | PIK3CA 1842/4885KDM4C 3408/4885KDM5A 4132/4885 |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP1B1 | PIK3CA 3938/4885KDM4C 1182/4885KDM5A 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.